NAIROBI, Kenya — Kenyatta University Teaching, Referral and Research Hospital (KUTRRH) has become the first public hospital in the region to offer Lutetium-177 PSMA therapy, a major milestone in the treatment of advanced prostate cancer.
The hospital announced the development on Monday, describing the therapy as a breakthrough targeted treatment for patients who no longer respond to conventional cancer care.
Lutetium-177 PSMA therapy delivers radiation directly to prostate cancer cells, minimizing damage to surrounding healthy tissue. This targeted approach significantly reduces side effects while improving treatment outcomes for patients with advanced disease.
KUTRRH said the therapy marks a major step forward in expanding access to specialised cancer care within Kenya and the wider East African region.
“This advancement reinforces our commitment to world-class, accessible cancer care,” said KUTRRH Chief Executive Officer Dr Zeinab Gura.
She noted that the hospital continues to invest in advanced technologies to improve survival rates and quality of life for cancer patients.
Prostate cancer remains one of the leading causes of cancer-related deaths among men in Kenya, with many patients diagnosed at advanced stages when treatment options are limited.
Health experts say the introduction of Lutetium-177 PSMA therapy offers new hope to patients who have exhausted standard treatments such as surgery, chemotherapy and hormone therapy.
KUTRRH said the milestone aligns with the government’s Universal Health Coverage (UHC) agenda by bringing life-saving innovation closer to patients who would otherwise seek costly treatment abroad.
The hospital added that the move strengthens Kenya’s position as a regional hub for advanced cancer treatment and research.
